Alerce Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Alerce Investment Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-356,270	Closed	-$24.3M	–	7
2022 Q3	$24.3M	Buy	356,270 +230,000	+182%	+$12.7M	23.36%	3
2022 Q2	$4.03M	Hold	126,270	–	–	7.49%	6
2022 Q1	$4.37M	Hold	126,270	–	–	7.41%	6
2021 Q4	$3.7M	Hold	126,270	–	–	3.76%	7
2021 Q3	$3.22M	Hold	126,270	–	–	2.2%	7
2021 Q2	$4.42M	Hold	126,270	–	–	2.4%	7
2021 Q1	$5.15M	Hold	126,270	–	–	2.28%	7
2020 Q4	$5.47M	Buy	+126,270	New	+$6.23M	2.15%	7

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alerce Investment Management's GBT Position: Q4 2022 in Review

Alerce Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 356,270 shares — an estimated $24.3M sold.

Alerce Investment Management first reported a position in GBT in Q4 2020 and held it in 8 quarters. The position peaked at $24.3M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Alerce Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Alerce Investment Management sold 356,270 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $24.3M.
Alerce Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 8 quarters.
Alerce Investment Management's Global Blood Therapeutics, Inc. position peaked at $24.3M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Alerce Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.